Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection

A. M. Segura, O. Gutiérrez, W. Otero, A. Angel, R. M. Genta, D. Y. Graham

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: Metronidazole-resistant Helicobacter pylori are generally the rule in developing countries such as Colombia. Developing countries need an effective, simple and inexpensive non-metronidazole therapy for H. pylori infection. Aim: To evaluate the combination of bismuth, furazolidone and amoxycillin for the treatment of H. pylori infection in Colombia. Methods: Thirty patients with histologically documented H. pylori infection received the combination of bismuth subcitrate 240 mg b.d., furazolidone 100 mg q.d.s. and amoxycillin 500 mg q.d.s. for 14 days. Four or more weeks after ending therapy patients were re-endoscoped and gastric biopsies were obtained and examined using the Genta stain. Each slide was scored for presence, absence and density of H. pylori, active and chronic inflammation, intestinal metaplasia, erosions and atrophy. Cure was defined as the absence of H. pylori. Results: All patients completed the course of therapy. Twenty-five patients were cured (86%, 95% CI: 6594%). Mild, well-tolerated side-effects were reported by six patients (20%). Conclusions: This combination of bismuth, furazolidone and amoxycillin fulfills the criteria for successful H. pylori therapy and appears particularly well suited for developing countries since it is simple, inexpensive and effective. Furazolidone-containing therapies may become especially useful in the face of a world-wide increase in H. pylori resistance to metronidazole and macrolides.

Original languageEnglish (US)
Pages (from-to)529-532
Number of pages4
JournalAlimentary Pharmacology and Therapeutics
Volume11
Issue number3
StatePublished - 1997

Fingerprint

Furazolidone
Bismuth
Amoxicillin
Helicobacter Infections
Helicobacter pylori
Developing Countries
Colombia
Metronidazole
Therapeutics
Macrolides
Metaplasia
Atrophy
Stomach
Coloring Agents
Inflammation
Biopsy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Segura, A. M., Gutiérrez, O., Otero, W., Angel, A., Genta, R. M., & Graham, D. Y. (1997). Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 11(3), 529-532.

Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. / Segura, A. M.; Gutiérrez, O.; Otero, W.; Angel, A.; Genta, R. M.; Graham, D. Y.

In: Alimentary Pharmacology and Therapeutics, Vol. 11, No. 3, 1997, p. 529-532.

Research output: Contribution to journalArticle

Segura, AM, Gutiérrez, O, Otero, W, Angel, A, Genta, RM & Graham, DY 1997, 'Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection', Alimentary Pharmacology and Therapeutics, vol. 11, no. 3, pp. 529-532.
Segura AM, Gutiérrez O, Otero W, Angel A, Genta RM, Graham DY. Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics. 1997;11(3):529-532.
Segura, A. M. ; Gutiérrez, O. ; Otero, W. ; Angel, A. ; Genta, R. M. ; Graham, D. Y. / Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. In: Alimentary Pharmacology and Therapeutics. 1997 ; Vol. 11, No. 3. pp. 529-532.
@article{9823a95eaf6841619b24f55897160f7c,
title = "Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection",
abstract = "Background: Metronidazole-resistant Helicobacter pylori are generally the rule in developing countries such as Colombia. Developing countries need an effective, simple and inexpensive non-metronidazole therapy for H. pylori infection. Aim: To evaluate the combination of bismuth, furazolidone and amoxycillin for the treatment of H. pylori infection in Colombia. Methods: Thirty patients with histologically documented H. pylori infection received the combination of bismuth subcitrate 240 mg b.d., furazolidone 100 mg q.d.s. and amoxycillin 500 mg q.d.s. for 14 days. Four or more weeks after ending therapy patients were re-endoscoped and gastric biopsies were obtained and examined using the Genta stain. Each slide was scored for presence, absence and density of H. pylori, active and chronic inflammation, intestinal metaplasia, erosions and atrophy. Cure was defined as the absence of H. pylori. Results: All patients completed the course of therapy. Twenty-five patients were cured (86{\%}, 95{\%} CI: 6594{\%}). Mild, well-tolerated side-effects were reported by six patients (20{\%}). Conclusions: This combination of bismuth, furazolidone and amoxycillin fulfills the criteria for successful H. pylori therapy and appears particularly well suited for developing countries since it is simple, inexpensive and effective. Furazolidone-containing therapies may become especially useful in the face of a world-wide increase in H. pylori resistance to metronidazole and macrolides.",
author = "Segura, {A. M.} and O. Guti{\'e}rrez and W. Otero and A. Angel and Genta, {R. M.} and Graham, {D. Y.}",
year = "1997",
language = "English (US)",
volume = "11",
pages = "529--532",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection

AU - Segura, A. M.

AU - Gutiérrez, O.

AU - Otero, W.

AU - Angel, A.

AU - Genta, R. M.

AU - Graham, D. Y.

PY - 1997

Y1 - 1997

N2 - Background: Metronidazole-resistant Helicobacter pylori are generally the rule in developing countries such as Colombia. Developing countries need an effective, simple and inexpensive non-metronidazole therapy for H. pylori infection. Aim: To evaluate the combination of bismuth, furazolidone and amoxycillin for the treatment of H. pylori infection in Colombia. Methods: Thirty patients with histologically documented H. pylori infection received the combination of bismuth subcitrate 240 mg b.d., furazolidone 100 mg q.d.s. and amoxycillin 500 mg q.d.s. for 14 days. Four or more weeks after ending therapy patients were re-endoscoped and gastric biopsies were obtained and examined using the Genta stain. Each slide was scored for presence, absence and density of H. pylori, active and chronic inflammation, intestinal metaplasia, erosions and atrophy. Cure was defined as the absence of H. pylori. Results: All patients completed the course of therapy. Twenty-five patients were cured (86%, 95% CI: 6594%). Mild, well-tolerated side-effects were reported by six patients (20%). Conclusions: This combination of bismuth, furazolidone and amoxycillin fulfills the criteria for successful H. pylori therapy and appears particularly well suited for developing countries since it is simple, inexpensive and effective. Furazolidone-containing therapies may become especially useful in the face of a world-wide increase in H. pylori resistance to metronidazole and macrolides.

AB - Background: Metronidazole-resistant Helicobacter pylori are generally the rule in developing countries such as Colombia. Developing countries need an effective, simple and inexpensive non-metronidazole therapy for H. pylori infection. Aim: To evaluate the combination of bismuth, furazolidone and amoxycillin for the treatment of H. pylori infection in Colombia. Methods: Thirty patients with histologically documented H. pylori infection received the combination of bismuth subcitrate 240 mg b.d., furazolidone 100 mg q.d.s. and amoxycillin 500 mg q.d.s. for 14 days. Four or more weeks after ending therapy patients were re-endoscoped and gastric biopsies were obtained and examined using the Genta stain. Each slide was scored for presence, absence and density of H. pylori, active and chronic inflammation, intestinal metaplasia, erosions and atrophy. Cure was defined as the absence of H. pylori. Results: All patients completed the course of therapy. Twenty-five patients were cured (86%, 95% CI: 6594%). Mild, well-tolerated side-effects were reported by six patients (20%). Conclusions: This combination of bismuth, furazolidone and amoxycillin fulfills the criteria for successful H. pylori therapy and appears particularly well suited for developing countries since it is simple, inexpensive and effective. Furazolidone-containing therapies may become especially useful in the face of a world-wide increase in H. pylori resistance to metronidazole and macrolides.

UR - http://www.scopus.com/inward/record.url?scp=0030851613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030851613&partnerID=8YFLogxK

M3 - Article

C2 - 9218077

AN - SCOPUS:0030851613

VL - 11

SP - 529

EP - 532

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 3

ER -